Total Valuation
Imugene has a market cap or net worth of $29.27M. The enterprise value is $97.38.
Market Cap$29.27M
Enterprise Value$97.38
Share Statistics
Imugene has 489,719,850 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding489,719,850
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Imugene’s return on equity (ROE) is -1.53 and return on invested capital (ROIC) is -96.44%.
Return on Equity (ROE)-1.53
Return on Assets (ROA)-0.83
Return on Invested Capital (ROIC)-96.44%
Return on Capital Employed (ROCE)-1.15
Revenue Per Employee293.12K
Profits Per Employee-4.60M
Employee Count15
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Imugene is ―. Imugene’s PEG ratio is 0.02.
PE Ratio―
PS Ratio21.99
PB Ratio2.15
Price to Fair Value2.15
Price to FCF-1.07
Price to Operating Cash Flow-0.39
PEG Ratio0.02
Income Statement
In the last 12 months, Imugene had revenue of 4.40M and earned -69.02M in profits. Earnings per share was -0.32.
Revenue4.40M
Gross Profit4.40M
Operating Income-70.94M
Pretax Income-69.02M
Net Income-69.02M
EBITDA-67.42M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -62.92M and capital expenditures 3.21M, giving a free cash flow of -59.70M billion.
Operating Cash Flow-62.92M
Free Cash Flow-59.70M
Free Cash Flow per Share-0.12
Dividends & Yields
Imugene pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.91
52-Week Price Change-65.56%
50-Day Moving Average0.09
200-Day Moving Average0.16
Relative Strength Index (RSI)34.64
Average Volume (3m)16.95K
Important Dates
Imugene upcoming earnings date is Sep 2, 2026, TBA (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateSep 2, 2026
Ex-Dividend Date―
Financial Position
Imugene as a current ratio of 1.88, with Debt / Equity ratio of 12.00%
Current Ratio1.88
Quick Ratio1.88
Debt to Market Cap0.10
Net Debt to EBITDA0.17
Interest Coverage Ratio-436.59
Taxes
In the past 12 months, Imugene has paid -4.04M in taxes.
Income Tax-4.04M
Effective Tax Rate0.06
Enterprise Valuation
Imugene EV to EBITDA ratio is -1.27, with an EV/FCF ratio of -0.95.
EV to Sales19.42
EV to EBITDA-1.27
EV to Free Cash Flow-0.95
EV to Operating Cash Flow-1.13
Balance Sheet
Imugene has $14.14M in cash and marketable securities with $5.02M in debt, giving a net cash position of $9.11M billion.
Cash & Marketable Securities$14.14M
Total Debt$5.02M
Net Cash$9.11M
Net Cash Per Share$0.02
Tangible Book Value Per Share$0.06
Margins
Gross margin is -65.91%, with operating margin of -1613.45%, and net profit margin of -1569.81%.
Gross Margin-65.91%
Operating Margin-1613.45%
Pretax Margin-1569.81%
Net Profit Margin-1569.81%
EBITDA Margin-1533.46%
EBIT Margin-1593.52%
Analyst Forecast
The average price target for Imugene is $0.18, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$0.18
Price Target Upside75.28% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast63.44%